| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |




* From the Departments of Respiratory Therapy and
Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei; and
the Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Address correspondence to: Dr. Hsiang-Ning Luk, Associate Professor, Department of Anesthesiology, Chang Gung Memorial Hospital, No 5, Fu-Hsin Street, Kwei-Shan Hsiang, Taoyuan, Taiwan. Phone/Fax: 886-3-328-3110; E-mail: luk1015{at}adm.cgmh.org.tw
| Abstract |
|---|
|
|
|---|
Clinical features: A 79-yr-old man with pneumoconiosis complicated by cor pulmonale suffered from gout-related cellulitis of the left lower limb. Debridement of the left gangrenous big toe was carried out under general anesthesia. During anesthesia, a wide-QRS tachycardia occurred suddenly and a complex atrial tachyarrhythmia was later diagnosed. Hemodynamics deteriorated despite aggressive treatment with lidocaine, verapamil, direct current cardioversion, magnesium, digoxin and amiodarone. Correction of the underlying respiratory acidosis was not sufficient to control the rapid ventricular response. Eventually, iv diltiazem adequately controlled the rapid ventricular rate and quickly improved the deteriorating hemodynamics.
Conclusion: Life-threatening complex atrial tachyarrhythmias may occur in patients with chronic lung diseases perioperatively. Intravenous diltiazem was effective in the management of complex atrial tachyarrhythmia in a patient with underlying cor pulmonale.
| Introduction |
|---|
|
|
|---|
| Case report |
|---|
|
|
|---|
|
During emergence from anesthesia, the laryngeal mask was removed and replaced by a facial mask to assist ventilation. Unexpectedly, the patient awoke abruptly, manifested cold sweating and air hunger. Urgent blood gas analysis revealed respiratory acidosis (pH 7.159, PO2 203.9 mmHg, PCO2 75.8 mmHg, base excess (BE) -1.8 mM, K+ 5.4 mM, ionized Ca2+ 0.94 mM) and the ventilation rate was increased to correct the acidosis. At the same time, wide-QRS tachycardia with a ventricular rate of 150200 beatsmin-1 was noted (Figure 2A
). Blood pressure was still stable (158/72 mmHg). Lidocaine (1 mgkg-1, iv) was administered twice, but was ineffective in converting the rhythm. After detailed examination of the ECG, supraventricular tachycardia with aberrant conduction and multifocal atrial tachycardia (MAT) were highly suspected. Therefore, verapamil (3 mg, iv) was given in titration. It was still not effective. Although the follow-up gas analysis revealed that respiratory acidosis had been corrected via manual hyperventilation (pH 7.4, PO2 74.1 mmHg, PCO2 40.0 mmHg, BE -0.1 mM, K+ 4.0 mM, ionized Ca2+ 0.74 mM), the rapid ventricular response persisted (170 beatsmin-1). The patient was sent to the postanesthesia care unit (PACU) for further treatment. In the PACU, due to the deteriorating hemodynamic status as manifested principally by hypotension (50/30 mmHg), direct current cardioversion (50 joules) was applied after administration of lidocaine (50 mg, iv). Meanwhile, sodium bicarbonate and calcium gluconate were supplemented based on blood gas analysis data (pH 7.270, PO2 74.0 mmHg, PCO2 38.0 mmHg, BE -8.2 mM, K+ 3.98 mM, ionized Ca2+ 0.76 mM). Magnesium sulfate (1 gm, iv) was infused slowly and the rhythm was converted to sinus tachycardia with occasional short-runs of atrial tachycardia (Figure 2B
). Subsequently, iv amiodarone (300 mg, iv for ten minutes, followed by 900 mgday-1 iv infusion) was administered in order to control the atrial arrhythmia. However, the rhythm reversed to Af with rapid ventricular response (160 min, Figure 2C
). The sustained rapid ventricular response was associated with persistent hypotension (80/60 mmHg) and the need to decrease ventricular rate was imperative. We administered diltiazem (20 mg, iv, for 15 min) as a last resort. Eventually, sinus rhythm resumed with short-runs of atrial tachycardia but the ventricular rate was slower (115120 min; Figure 3
). Acid-base imbalance was corrected (pH 7.4, PO2 100 mmHg, PCO2 34 mmHg, BE -1.7 mM, SaO2 98% at FiO2 40%, K+ 3.96 mM, ionized Ca2+ 0.82 mM). The patients blood pressure became stable (120/60 mmHg) and he recovered consciousness. The entire episode of rapid ventricular response lasted for four hours before it could be effectively controlled.
|
|
|
| Discussion |
|---|
|
|
|---|
The incidence of arrhythmias is variable in patients with chronic obstructive lung diseases.1,3 Various factors are potentially arrhythmogenic, such as hypercapnia, acid-base imbalance, hypokalemia, digitalis, methylxanthines, ß-a drenergic agonists, aerosol propellants, steroids, ethanol, coronary heart disease, and cor pulmonale. The presence of ventricular arrhythmias in patients with chronic obstructive pulmonary disease (COPD) is thought to be associated with high in-hospital mortality and pedal edema, elevated PCO2, and masculine gender are predictors of repetitive arrhythmias in chronic lung diseases.3,4 However, history of coronary heart disease, increased sinus heart rate and decreased maximum work load rather than arrhythmias per se are predictors of death.3 In addition to ventricular arrhythmias, several types of supraventricular tachyarrhythmias may occur in patients with COPD, such as MAT, Af and flutter (AF).2 In this patient, the exact mechanism responsible for the arrhythmias observed is not clear. The later stage of pneumoconiosis is usually complicated by cor pulmonale and therefore the incidence of arrhythmias is increased. Our patient presented with signs of exertional dyspnea and pedal edema. Since the patient suffered from wound infection with possible septicemia, this condition might further predispose him to the danger of atrial arrhythmias. It has recently been demonstrated that systemic inflammatory response syndrome and sepsis are independent risk factors for the development of atrial tachyarrhythmias.57 During induction and maintenance of anesthesia, sympathetic stimulation and hypercapnia could also precipitate the preexisting arrhythmia into MAT and Af, eventually, resulting in intractable rapid ventricular response and impending tachycardia-induced heart failure.
Atrial tachyarrhythmias, although not necessarily life-threatening, may cause thromboembolism, compromise of cardiac output, tachycardia-induced heart failure and poor quality of life. Although invasive radiofrequency catheter ablation has been demonstrated to be effective in certain types of atrial tachyarrhythmias,8,9 medical treatment is still the mainstay of therapy. In patients with atrial tachyarrhythmias, rate control should be placed before rhythm control.10,11 Thus, pharmacological agents that depress conduction and prolong refractoriness of the atrioventricular (AV) node are frequently required for the control of symptoms and improvement of hemodynamics during Af before the use of other antiarrhythmic agents capable of converting the rhythm. Paradoxical acceleration of the ventricular rate has been reported when patients with atrial tachyarrhythmias are treated with rhythm-control agents such as quinidine, propafenone, or even amiodarone, without having received AV node blocking agents. This situation also happened in our patient. Amiodarone paradoxically accelerated his ventricular rate (Figure 2C
). Moreover, amiodarone should be used with caution in patients with decreased diffusion capacity, such as in this patient with pneumoconiosis. It is known that the incidence of amiodarone-induced pulmonary toxicity is about 5.8%.12 The risk factors of pulmonary toxicity include advanced age, higher amiodarone maintenance dose, and lower DLCO.12,13 Although amiodarone may be safely used in patients with heart failure and COPD,14 short-term use of amiodarone can still cause acute or fatal pulmonary toxicity.12,15,16 It should also be noted that the outcome of long-term use of oral amiodarone in patients with pneumoconiosis with cor pulmonale remains to be evaluated.
Drugs that prolong refractoriness and decrease conduction velocity in the AV node include digoxin, ß-adrenergic antagonists, magnesium and calcium channel blockers. The electrophysiological actions of digoxin on the AV node are principally indirect and depend on cardiac innervation. Furthermore, the onset of its therapeutic effect is slow, at least 60 min after administration in most patients, with the full effect taking place in up to six hours. Therefore, iv digoxin was not the first choice to control the rapid ventricular response in this patient. Although ß-blockers are now indicated in patients with compensated congestive heart failure, only chronic oral use of either one of the three ß-blockers (metoprolol, bisoprolol, and carvedilol) is proven to be effective in patients with chronic stable heart failure. Intravenous ß-blocker treatment is not a standard therapy in congestive heart failure. In this patient, left and right ventricular ejection fractions were 32% and 28%, respectively. In addition, although cardioselective ß-blockers could be used in the patients with mild to moderate reversible airway diseases, their effects in severe COPD or during exacerbation are inconclusive at this moment. In this patient, pulmonary function test showed FEV1 was only 0.98 L (42% of predicted value), TLC was 3.55 L (63% of predicted value) and RV/TLC was 61% (158% of predicted value). The findings suggested a moderate to severe combined obstructive and restrictive ventilatory dysfunction. In addition, diffuse wheezing was noted perioperatively. Therefore, iv esmolol was not considered in this patient, although it is effective in converting postoperative supraventricular tachyarrhythmias.1719
Magnesium did not prove to be effective in this patient, although it can be useful for COPD-related MAT.20,21 Oral verapamil is not absolutely contraindicated in patients with congestive heart failure. However, iv verapamil has a potent negative inotropic effect, excluding this agent from the list of rate controlling drugs in patients with congestive heart failure.22 Initial use of verapamil (3 mg, iv) was ineffective in this patient and later it was not supplemented because of deteriorating hemodynamics. According to the recently published advanced cardiac life support guideline, diltiazem, with its mild depressive effect on left ventricular function, can be used safely in conditions such as our patients.22 An iv bolus dose of diltiazem (2025 mg) resulted in a slowing of the ventricular rate in Af or AF in one multicentre study.23 The median time to therapeutic response was four minutes, and a continuous infusion of diltiazem (1015 mghr-1) could maintain a good control of ventricular rate. Intravenous diltiazem effectively achieved short-term control of heart rate.24 This treatment is particularly useful in patients with COPD complicated with supraventricular tachyarrhythmias which are triggered or exacerbated perioperatively. However, this advantage may be offset by a higher incidence of hypotension in critically ill patients with atrial tachyarrhythmias.25 It should be noted that more controlled clinical trials are needed to evaluate the optimal pharmacological management of Af in seriously ill patients.26
In summary, we report the case of a patient with pneumoconiosis complicated by cor pulmonale and biventricular dysfunction, who developed complex life-threatening atrial tachyarrhythmias perioperatively. Early accurate ECG diagnosis of the arrhythmia was obtained and iv diltiazem was effective in the treatment of the otherwise refractory atrial tachyarrhythmias.
Revision received October 17, 2002. Accepted for publication June 10, 2002.
| References |
|---|
|
|
|---|
2 Holford FD, Mithoefer JC. Cardiac arrhythmias in hospitalized patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1973; 108: 87985.[Medline]
3 Shih HT, Webb CR, Conway WA, Peterson E, Tilley B, Goldstein S. Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. Chest 1988; 94: 448.
4 Hudson LD, Kurt TL, Petty TL, Genton E. Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction. Chest 1973; 63: 6615.
5 Brathwaite D, Weissman C. The new onset of atrial arrhythmias following major noncardiothoracic surgery is associated with increased mortality. Chest 1998; 114: 4628.
6 Knotzer H, Mayr A, Ulmer H, et al. Tachyarrhythmias in a surgical intensive care unit: a case-controlled epidemiologic study. Intensive Care Med 2000; 26: 90814.[Medline]
7 Mayr A, Knotzer H, Pajk W, et al. Risk factors associated with new onset tachyarrhythmias after cardiac surgerya retrospective analysis. Acta Anaesthesiol Scand 2001; 45: 5439.[Medline]
8 Morady F. Radio-frequency ablation as treatment for cardiac arrhythmias. N Engl J Med 1999; 340: 53444.
9 Ueng KC, Lee SH, Wu DJ, Lin CS, Chang MS, Chen SA. Radiofrequency catheter modification of atrioventricular junction in patients with COPD and medically refractory multifocal atrial tachycardia. Chest 2000; 117: 529.
10 Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation. A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 1996; 93: 126277.
11 ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation). Developed in collaboration with the north American society of pacing and electrophysiology. Circulation 2001; 104: 211850.
12 Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82: 519.
13 Gleadhill IC, Wise RA, Schonfeld SA, et al. Serial lung function testing in patients treated with amiodarone: a prospective study. Am J Med 1989; 86: 410.[Medline]
14 Singh SN, Fisher SG, Deedwania PC, Rohatgi P, Singh BN, Fletcher RD. Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). J Am Coll Cardiol 1997; 30: 5147.[Abstract]
15 Kaushik S, Hussain A, Clarke P, Lazar HL. Acute pulmonary toxicity after low-dose amiodarone therapy. Ann Thorac Surg 2001; 72: 17601.
16 Kharabsheh S, Abendroth CS, Kozak M. Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone. Am J Cardiol 2002; 89: 8968.[Medline]
17 Hill GA, Owens SD. Esmolol in the treatment of multifocal atrial tachycardia. Chest 1992; 101: 17268.[Abstract]
18 Balser JR, Martinez EA, Winters BD, et al. ß-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology 1998; 89: 10529.[Medline]
19 Mooss AN, Wurdeman RL, Mohiuddin SM, et al. Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery. Am Heart J 2000; 140: 17680.[Medline]
20 McCord JK, Borzak S, Davis T, Gheoghiade M. Usefulness of intravenous magnesium for multifocal atrial tachycardia in patients with chronic obstructive pulmonary disease. Am J Cardiol 1998; 81: 913.[Medline]
21 Chiladakis JA, Stathopoulos C, Davlouros P, Manolis AS. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. Int J Cardiol 2001; 79: 28791.[Medline]
22 ECC Guidelines. Part 6: Advanced cardiovascular life support. Section 7: Algorithm approach to ACLS emergencies. Circulation 2000; 102(Suppl I): I13665.[Medline]
23 Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol 1991; 18: 8917.[Abstract]
24 Goldenberg IF, Lewis WR, Dias VC, Heywood JT, Pedersen WR. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol 1994; 74: 8849.[Medline]
25 Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001; 29: 114953.[Medline]
26 Khand AU, Rankin AC, Kaye GC, Cleland JGF. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J 2000; 21: 61432.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |